BACKGROUND: Liver hepatocellular carcinoma (LIHC) is a lethal cancer. This study 
aimed to identify the N6 -methyladenosine (m6 A)-targeted long non-coding RNA 
(lncRNA) related to LIHC prognosis and to develop an m6 A-targeted lncRNA model 
for prognosis prediction in LIHC.
METHODS: The expression matrix of mRNA and lncRNA was obtained, and 
differentially expressed (DE) mRNAs and lncRNAs between tumor and normal samples 
were identified. Univariate Cox and pathway enrichment analyses were performed 
on the m6 A-targeted lncRNAs and the LIHC prognosis-related m6 A-targeted 
lncRNAs. Prognostic analysis, immune infiltration, and gene DE analyses were 
performed on LIHC subgroups, which were obtained from unsupervised clustering 
analysis. Additionally, a multi-factor Cox analysis was used to construct a 
prognostic risk model based on the lncRNAs from the LASSO Cox model. Univariate 
and multivariate Cox analyses were used to assess prognostic independence.
RESULTS: A total of 5031 significant DEmRNAs and 292 significant DElncRNAs were 
screened, and 72 LIHC-specific m6 A-targeted binding lncRNAs were screened. 
Moreover, a total of 29 LIHC prognosis-related m6 A-targeted lncRNAs were 
obtained and enriched in cytoskeletal, spliceosome, and cell cycle pathways. An 
11-m6 A-lncRNA prognostic model was constructed and verified; the top 10 lncRNAs 
included LINC00152, RP6-65G23.3, RP11-620J15.3, RP11-290F5.1, RP11-147L13.13, 
RP11-923I11.6, AC092171.4, KB-1460A1.5, LINC00339, and RP11-119D9.1. 
Additionally, the two LIHC subgroups, Cluster 1 and Cluster 2, showed 
significant differences in the immune microenvironment, m6 A enzyme genes, and 
prognosis of LIHC.
CONCLUSION: The m6 A-lncRNA prognostic model accurately and effectively 
predicted the prognostic survival of LIHC. Immune cells, immune checkpoints 
(ICs), and m6 A enzyme genes could act as novel therapeutic targets for LIHC.